Congratulations to our biotech portfolio company adivo on its successful funding through the EIC Accelerator Program. This makes adivo one of only 99 highly innovative companies across Europe that the European Commission is supporting with a total of 627 million Euros to bring promising technologies to market.
adivo develops therapeutic antibodies for the treatment of serious and chronic diseases in companion animals. The EIC Accelerator Program will support the company to further develop their CAESAR-IBD project (treatment of canine inflammatory bowel disease) over the next two years and conduct initial clinical trials.
More information under the following Link.
More about adivo.
